Avita Medical, Inc. · NASDAQ:RCEL
Avita Medical — Q3 2025 Earnings Presentation
9 slides from Avita Medical's earnings presentation, Nov 6, 2025
Slide 1: Third Quarter 2025 Financial and Business Update
Third Quarter 2025 Financial and Business Update November 6, 2025
Slide 2: Forward-Looking Statements & Legal Disclaimers
Forward-Looking Statements & Legal Disclaimers 2024.Q4 v9 This presentation and the accompanying oral commentary may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are predictions and subject to significant risks and un
Slide 3: All seven MACs have now published or confirmed payment rates
All seven MACs have now published or confirmed payment rates, providing physicians with confidence of payment when using RECELL® Medicare Administrative Contractors (MACs) RVU Unconfirmed or Non-Confirmed Payment; Confirmed RVUs & Posting Date MAC Confirmed RVUs Accepted: Not Published Payment Avail
Slide 4: Clinical data and reimbursement now align to reinforce the full value of RECELL
Clinical data and reimbursement now align to reinforce the full value of RECELL for patients, clinicians, and hospitals Adoption Expanding utilization and patient access Predictable Payment Clinician and facility stability Category 1 CPT code Validated RECELL procedure Real-World Data Evidence demon
Slide 5: Focusing on ~200 key burn and trauma centers
Focusing on ~200 key burn and trauma centers - hospitals that we know well Long-Term Broad burn, trauma and surgical repair >$3.5B U.S. total addressable market (TAM) Immediate and scalable AVITA Focus growth potential • ~200 top burn and trauma centers • Covering the highest-volume accounts • Curre
Slide 6: Q3 revenue down year-over-year; operating expenses reduced through disciplined cost management
Q3 revenue down year-over-year; operating expenses reduced 24% through disciplined cost management Key figures Q3 Q3 % Change vs USD million 2024 2025 prior year Revenue 19.5 17.1 -13% Gross margin 1 83.7% 81.3% (240) bps RECELL-only gross margin was 83.6% for the quarter. Operating 30.2 23.0 -24% e
Slide 7: Net cash use improved to $6.2M in Q3 versus $10.1M in Q2
Net cash use improved to $6.2M in Q3 versus $10.1M in Q2 Cash, cash equivalents, and marketable securities USD million Cash use 10.1m Cash use 6.2m 13.8 Equity Underscores improving raise1 25.8 23.3 cash efficiency. 15.7 March 31, 2025 June 30, 2025 September 30, 2025 1) Raised $13.8 million, net af
Slide 8: Drive disciplined execution
Our focus in the fourth quarter Drive Position Refine our disciplined AVITA for commercial execution growth in focus 2026 8
Slide 9: Slide 9